MicroRNAs in cancer: biomarkers, functions and therapy.

By J. Hayes, Pierpaolo Peruzzi, S. Lawler. Trends in Molecular Medicine, 2014

1,984 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

MicroRNA (miRNA) in cancer (2015, background): “NGS is now emerging as a cost-effective option while bioinformatics analyses are no longer a major problem for continued usage [78,79].”
MicroRNA based Pan-Cancer Diagnosis and Treatment Recommendation (2017, positive): “With the advent of the TCGA pancancer analysis project, vast amounts of molecular and clinical data from tumorous and normal tissues, spanning over 34 different types of cancers, are at the fingertips of researchers [14].”
miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis (2020, methodology): “Manipulation of miRNAs could change the phenotypes in some NDs in experiments performed using animal models, so it is reasonable to expect to use miRNAs as therapeutic agents due to the small size of miRNA molecules [306].”